Effects of the changing from chlorofluorocarbon (CFC)- beclomethasone dipropionate (BDP) to hydrofluoroalkane (HFA)-BDP on pulmonary function in asthmatic children Source: Annual Congress 2007 - Anti-inflammatory therapy for childhood asthma Year: 2007
HFA beclomethasone dipropionate (HFA-BDP) extrafine aerosol and formoterol in optimizing the management of bronchial asthma at children Source: Eur Respir J 2005; 26: Suppl. 49, 159s Year: 2005
Protective effect of inhaled beclomethasone dipropionate (BDP) in asthmatic patients with exercise-induced bronchoconstriction (EIB) Source: Eur Respir J 2002; 20: Suppl. 38, 306s Year: 2002
Improvements in FEV1 and PEF were greater with salmeterol/fluticasone (S/F) than with beclamethasone dipropionate (BDP) Source: Eur Respir J 2004; 24: Suppl. 48, 380s Year: 2004
Improvements in FEV1 and PEF were greater with salmeterol/fluticasone (S/F) than with beclamethasone dipropionate (BDP) Source: Eur Respir J 2004; 24: Suppl. 48, 379s Year: 2004
Effects of extra fine formoterol or coarse particle salmeterol on impulse oscillometry (IOS) in corticosteroid treated persistent asthmatics Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015
Lung deposition and distribution of inhaled extra fine beclomethasone dipropionate / formoterol fumarate /glycopyrronium bromide (BDP/FF/GB) in subjects with and without airflow obstruction. Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021
Comparison of the anti-inflammatory effects of extra-fine HFA-beclomethasone (BDP) versus fluticasone (FP)-DPI on inflammatory markers in exhaled breath in childhood asthma Source: Annual Congress 2007 - Childhood asthma: treatment and follow-up Year: 2007
Acceptability and efficacy of beclomethasone dipropionate (Béclojet HFA®) and fluticasone dipropionate (Flixotide HFA®, FDP) associated with the Volumatic® spacer in adults with mild to moderate persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 473s Year: 2003
Systemic activity of inhaled beclomethasone dipropionate HFA: a comparison of volume spacers Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009
Use of hydrofluoroalkane beclomethasone dipropionate (HFA-BDP) extrafine aerosol in optimising the management of allergic bronchopulmonary aspergillosis (ABPA) Source: Eur Respir J 2003; 22: Suppl. 45, 237s Year: 2003
Treatment of exercise-induced asthma with beclomethasone dipropionate in children with asthma Source: Eur Respir J 2004; 24: 932-937 Year: 2004
QVAR pMDI is more cost-effective than fluticasone propionate (FP) or CFC-beclometasone dipropionate (BDP) PMDI in a real-life asthmatic population receiving an increase in ICS dose Source: Annual Congress 2009 - Sustainability in treatment of COPD patients according to economics and quality of care Year: 2009
A comparison of salmeterol xinafoate (SX) plus beclomethasone dipropionate (BDP) and theophylline (Theo) plus BDP in the treatment of moderate chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2005; 26: Suppl. 49, 292s Year: 2005
Comparison of HFA salmeterol-fluticasone (SFC) combination when given through breath actuated inhaler (BAI) and pressurised meter dose inhaler (pMDI) in patients with moderate-to-severe asthma Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013
Comparison of a new extrafine beclomethasone dipropionate HFA134a-formulated pMDI with a standard BDP CFC pMDI in adults with moderate persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 206s Year: 2006
A comparison of the efficacy of salmeterol/fluticasone propionate combination (SF) with beclometasone dipropionate (BDP) delivered via metered dose inhaler (MDI) in patients not well controlled on bronchodilators alone Source: Eur Respir J 2001; 18: Suppl. 33, 53s Year: 2001
A comparison of the efficacy of beclomethasone dipropionate (BDP) and fluticasone propionate (FP) aqueous nasal spray on symptoms and quality of life in perennial allergic rhinitis Source: Eur Respir J 2003; 22: Suppl. 45, 110s Year: 2003
QVAR pMDI is more cost effective than CFC-beclometasone dipropionate (BDP) pMDI in a real-life asthmatic population initiating ICS Source: Annual Congress 2009 - Sustainability in treatment of COPD patients according to economics and quality of care Year: 2009
Comparison of the effects of beclomethasone HFA (BDP- HFA) pMDI with beclomethasone CFC (BDP-CFC) pMDI on 10-hour urinary cortisol in healthy subjects Source: Annual Congress 2008 - Advances in the treatment and pathogenesis of pulmonary diseases Year: 2008